Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling

Date

28 Sep 2019

Session

Poster Display session 1

Presenters

Minakshi Mann

Citation

Annals of Oncology (2019) 30 (suppl_5): v1-v24. 10.1093/annonc/mdz238

Authors

M. Mann1, S. Kumar1, A. Sharma2, S.S. Chauhan2, N. Bhatla3, S. Kumar3, S. Bakhshi1, R. Gupta4, L. Kumar1

Author affiliations

  • 1 Medical Oncology, All India Institute of Medical Sciences, 110029 - Delhi/IN
  • 2 Biochemistry, All India Institute of Medical Sciences, 110029 - Delhi/IN
  • 3 Obstetrics And Gynaecology, All India Institute of Medical Sciences, 110029 - Delhi/IN
  • 4 Laboratory Oncology, All India Institute of Medical Sciences, 110029 - Delhi/IN
More

Resources

Abstract 1314

Background

Cisplatin (CDDP) is used in the treatment of locally advanced disease (FIGO stage IIB-IVA) as well recurrent/metastatic cervical cancer. However toxic side effects and acquired resistance limits its efficacy. Enhanced DNA repair is one of the mechanisms responsible for acquired cisplatin resistance. Poly(ADP-ribose) polymerase (PARP) inhibitors have been approved for treating BRCA mutated cancers like breast and ovary cancer, however, little is known about the therapeutic efficacy and mechanism of action of PARP inhibitors in non-BRCA cancer like cervical cancer, either as a single agent or in combination with cisplatin.

Methods

Effect of PARP-1 inhibition (PJ34/PARP-1siRNA) was determined in vitro on cell viability, apoptosis, cell cycle progression, proliferation, invasion and metastasis, clonogenecity and β-catenin signaling in cervical cancer cell lines HeLa and SiHa.

Results

Combination of CDDP with PJ34 or PARP-1 siRNA significantly reduced the cell proliferation and induced cell cycle arrest and apoptosis. Also, a significant decrease in cell survival as well as cell invasion and migration was observed as compared with either CDDP/PJ34 alone. The enhanced CDDP sensitivity by PARP-1 inhibition was determined to be due to inhibition of β-catenin signaling as shown by a decrease in MMP-2 activity, MMP-9, c-myc and cyclin-D1 expression upon treatment with PJ34 and PARP-1 siRNA.

Conclusions

Our data provides experimental evidence on the contribution of PARP-1 inhibition in enhancing the cytotoxicity of CDDP in cervical cancer cells. We also present novel findings on the suppression of β-catenin and its downstream signaling components by PARP-1 inhibitor.

#: 5μM of CDDP was used both alone and in combination with PJ34; ##: A gradient of CDDP from 0-15μM was used to evaluate the combined effect of PJ34 and CDDP on IC50 value of CDDP. p: *<0.05, **<0.01. (H): HeLa; (S): SiHa.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

All India Institute of Medical Sciences.

Disclosure

All authors have declared no conflicts of interest.Table: 67P

Combined effect of PJ34 and CDDP on cisplatin sensitivity in cervical cancer cell lines

Cancer cell parameterOnly CDDP (10μM)Only PJ34 (10μM)CDDP(10μM) + PJ34(10μM)p value/fold difference
Clonogenic formation fraction#0.23 ± 0.08 (H) 0.31± 0.06 (S)0.67 ± 0.09 (H) 0.65 ± 0.01 (S)0.13 ± 0.05 (H) 0.15 ± 0.07 (S)* (H) * (S)
Fold migration0.71 ± 0.06 (H) 0.75 ± 0.03 (S)0.89 ± 0.07 (H) 0.99 ± 0.08 (S)0.54 ± 0.05 (H) 0.34 ± 0.02 (S)** (H) * (S)
Relative invasion43.4 ± 2.25 (H) 47.9 ± 7.07 (S)66.6 ± 5.94 (H) 70.5 ± 5.74 (S)15.8 ± 2.81 (H) 23.4± 4.13 (S)** (H) ** (S)
IC50 value##8.25μM (H) 10.8μM (S)31.5μM (H) 33.0μM (S)3.6μM (H) 3.4μM (S)2.29 fold 3.18 fold

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings